GlassScriptPhysician profile
Michael P Schulte
NPI 1043247141
$5,342.84
in general payments reported to CMS, 2019-2025
38 companies · $1,046 in 2025
The $1,046 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $231 · 2021: $1,033 · 2022: $785 · 2023: $982 · 2024: $1,110 · 2025: $1,046.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,137.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,622.41 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $611.07 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $392.55 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $353.39 | 2020-2025 | |
| Amgen INC. | $324.56 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.29 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $230.61 | 2020-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $184.25 | 2022-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $137.78 | 2021-2025 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $134.07 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $92.49 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $79.07 | 2019-2022 | |
| Amarin Pharma, INC. | $73.64 | 2020-2021 | |
| Allergan, INC. | $62.89 | 2019 | |
| Corium, LLC | $62.24 | 2022-2024 | Azstarys |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schulte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.